TEL
AVIV, Israel, May 4, 2022
/PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB),
(Chemomab), a clinical-stage biotechnology company focused on the
discovery and development of innovative therapeutics for fibrotic
and inflammatory diseases with high unmet need, today announced the
company will release its first quarter 2022 financial results and
provide a business update on Thursday, May
12, 2022. The company will host a conference call at
8:00 am Eastern Time, which will be
webcast at the link below and on the company's investor relations
website.
Chemomab's management team will review first quarter 2022
performance, discuss recent and upcoming events and conduct a live
question-and-answer session.
Conference Call and Webcast Information:
Live Webcast at 8:00 am ET,
May 12, 2022
Click this Webcast link to access the live webcast or
replay.
The live webcast and replay can also be accessed at the News
& Events section of the Investors page on
the Chemomab website
at investors.chemomab.com/events.
By Telephone
Conference call information:
US Investors:
+1 (877) 407-9208
International Investors: +1 (201) 493-6784
Conference ID: 13728593
Please call 5-10 minutes before the scheduled start time and
ask for the Chemomab conference call.
About Chemomab Therapeutics
Chemomab is a
clinical-stage biotechnology company focusing on the discovery and
development of innovative therapeutics for fibrotic and
inflammatory diseases with high unmet need. Based on the unique and
pivotal role of the soluble protein CCL24 in promoting fibrosis and
inflammation, Chemomab developed CM-101, a monoclonal antibody
designed to bind and block CCL24 activity. CM-101 has demonstrated
the potential to treat multiple severe and life-threatening
fibrotic and inflammatory diseases. It is currently in two Phase 2
safety and efficacy trials—one in patients with primary sclerosing
cholangitis and the second in patients with liver fibrosis, with a
third Phase 2 trial in systemic sclerosis expected to begin in
2022.
For more information on Chemomab, visit chemomab.com
Contacts:
Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1 (917) 734-7387
ir@chemomab.com
Media:
Barbara Lindheim
Chemomab Therapeutics
Consulting Vice President
Investor & Public Relations,
Strategic Communications
Phone: +1 (917) 355-9234
barbara@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-report-first-quarter-2022-financial-results-and-provide-a-business-update-301539391.html
SOURCE Chemomab Therapeutics, Ltd.